Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neeraj Gupta

Showing results (321-330 of 353) with videos related to

Pageof 36
Sort By:
Blood|May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosisVaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
Journal of Hematology & Oncology|September 5, 2015
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyNeeraj Gupta, Yeow Tee Goh, Chang-Ki Min, et al.
The Indian Journal of Tuberculosis|November 9, 2021
Thoracoscopic practices in India-a survey by Indian chest societyRakesh K Chawla, D J Christopher, Raja Dhar, et al.
Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine|December 17, 2021
COVID-19-associated Multisystem Inflammatory Syndrome in Children: A Multicentric Retrospective Cohort StudyBharat Mehra, Mukul Pandey, Dhiren Gupta, et al.
Journal of Clinical Pharmacology|August 12, 2017
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic AnalysisNeeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, et al.
Indian Pediatrics|August 28, 2024
Comparative Efficacy of Interventions for Analgesia During Heel Prick in Newborn Infants - A Systematic Review and Network Meta-AnalysisThangaraj Abiramalatha, Viraraghavan Vadakkencherry Ramaswamy, Rajendra Prasad Anne, et al.
Haematologica|June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myelomaJesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
American Journal of Industrial Medicine|November 19, 2009
Occupational health crossing borders part 2: Comparison of 18 occupational health systems across the globeKatja Radon, Vera Ehrenstein, Dennis Nowak, et al.
Lung India : Official Organ of Indian Chest Society|January 6, 2021
Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registrySheetu Singh, Mohan Bairwa, Bridget F Collins, et al.
British Journal of Haematology|June 26, 2018
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myelomaPaul G Richardson, Craig C Hofmeister, Cara A Rosenbaum, et al.
Pageof 36

Showing results (321-330 of 353) with videos related to

Sort By:
Pageof 36
Blood|May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosisVaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
Journal of Hematology & Oncology|September 5, 2015
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyNeeraj Gupta, Yeow Tee Goh, Chang-Ki Min, et al.
The Indian Journal of Tuberculosis|November 9, 2021
Thoracoscopic practices in India-a survey by Indian chest societyRakesh K Chawla, D J Christopher, Raja Dhar, et al.
Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine|December 17, 2021
COVID-19-associated Multisystem Inflammatory Syndrome in Children: A Multicentric Retrospective Cohort StudyBharat Mehra, Mukul Pandey, Dhiren Gupta, et al.
Journal of Clinical Pharmacology|August 12, 2017
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic AnalysisNeeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, et al.
Indian Pediatrics|August 28, 2024
Comparative Efficacy of Interventions for Analgesia During Heel Prick in Newborn Infants - A Systematic Review and Network Meta-AnalysisThangaraj Abiramalatha, Viraraghavan Vadakkencherry Ramaswamy, Rajendra Prasad Anne, et al.
Haematologica|June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myelomaJesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
American Journal of Industrial Medicine|November 19, 2009
Occupational health crossing borders part 2: Comparison of 18 occupational health systems across the globeKatja Radon, Vera Ehrenstein, Dennis Nowak, et al.
Lung India : Official Organ of Indian Chest Society|January 6, 2021
Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registrySheetu Singh, Mohan Bairwa, Bridget F Collins, et al.
British Journal of Haematology|June 26, 2018
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myelomaPaul G Richardson, Craig C Hofmeister, Cara A Rosenbaum, et al.
Pageof 36